currently the most widely investigated agents for the Introduction treatment of patients with Alzheimer's disease. However, the use of existing agents, such as tacrine, is hampered by Alzheimer's disease has been estimated to affect approximately 5-10% of the population over age 65, and as many lack of specificity for acetylcholinesterase (AChE), resulting in unwanted peripheral cholinergic side-effects [4] [5] [6] [7] . as 50% of those older than 85 years of age [1] . Despite its prevalence, the aetiology of the condition remains poorly Tacrine and other agents are also short-acting and require administration several times a day, a factor that may understood. Alzheimer's disease is recognized pathologically by the demonstration at autopsy of amyloid plaques and compromise patient compliance and have a direct impact on therapeutic success. Further, the acridine-based cholinneurofibrillary tangles in the areas of the cerebral cortex where cholinergic pathways have been destroyed [2] . There esterase inhibitors, such as tacrine, are associated with significant hepatotoxicity and thus require regular transaminis a general consensus that the cholinergic deficit resulting from impairment of cholinergic neurotransmission is rease monitoring [4, 8] . Donepezil HCl (also known as E2020 or AriceptA, the sponsible for the deficits in memory and cognition that characterize the condition [3] . registered trademark of Eisai Co. Ltd, Tokyo, Japan) is the product of a specific research programme undertaken to Various therapeutic strategies to counteract the cognitive symptoms of Alzheimer's disease have been investigated. produce a treatment for Alzheimer's disease. It was shown to have specific activity for AChE with little activity for These include nicotinic and muscarinic agonists, as well as neuroprotective agents. The cholinesterase inhibitors are butyrylcholinesterase (BuChE) [9] [10] [11] . The unique piperidine-based structure of donepezil makes it chemically and pharmacologically distinct from other cholinesterase inhibi-high selectivity for AChE isolated from rat brain tissue, is On days 1, 7, 14 and 21, the subjects observed a 12 h fast from food and fluids (except water) prior to dose adminiswithout effect on cholinesterases isolated from cardiac muscle or intestinal smooth muscle, and has only marginal tration and collection of blood samples for clinical laboratory and analytical evaluations. The subjects remained awake and effect on striatal muscle cholinesterase [12, 13] . The ability of donepezil to increase brain acetylcholine (ACh) was in an upright position (>45°angle from supine) for 4 h after drug administration. The subjects stayed at the demonstrated by ex vivo and in vivo measurements of brain ACh. These increases in brain ACh were associated with investigational site for 30 days until all of the follow-up assessments had been completed. During this time they improved performance in behavioural, learning and memory function tests in rats with experimentally induced cholinergic abstained from caffeine-containing beverages, and physical exertion was limited to normal walking. hypofunction [12, 14] . Furthermore, donepezil was found to be devoid of toxicity in 1-year studies in rats and dogs and, perhaps most importantly, not hepatotoxic [13] .
Sample collection and analysis The pharmacokinetics of donepezil following single-dose administration are reported in this supplement. The present Venous blood samples (7 ml) for the measurement of donepezil concentrations in plasma and AChE activity in study was designed to characterize fully the pharmacokinetics and pharmacodynamics of donepezil HCl associated with red blood cell membranes (rbc-AChE) were collected in evacuated heparinized tubes at 1, 2, 2.5, 3, 3.5, 4, 6, 8, 12 multiple-dose 
Subjects
Blood samples were placed on ice immediately after collection. Plasma was then separated from the cellular The study population comprised a total of 27 healthy, ambulatory, non-smoking men, between 19 and 40 years of components by centrifugation. The plasma-rbc interface was marked on the tube and the 2 ml plasma phase was age. Their body weights ranged between 65 and 85 kg, and all were within 15% of ideal weight, based on the then harvested and stored at −20°C until analysis. Following the removal of the plasma for pharmacokinetic Metropolitan Insurance Company Height and Weight Tables  (1983) . Upon clinical examination, subjects were found to measurement, the white blood cell/platelet layer and the top 3 mm of the rbc layer were removed using a Pasteur be free from significant hepatic, gastrointestinal, renal, respiratory, endocrine, haematological, neurological, psychipipette and discarded. The remaining rbcs were gently vortexed before being stored in an upright position at atric or cardiovascular system abnormalities. None had a known or suspected history of alcohol or drug misuse and −20°C in polypropylene Sarstedt tubes until analysis. Plasma concentrations of donepezil were quantified using a none had taken over-the-counter medications or consumed alcoholic beverages for at least 48 h prior to enrolment. No specific and sensitive high-performance liquid chromatography (HPLC) method with ultraviolet (UV) detection investigational or prescription medications had been taken within 1 month of entry into the study.
[16]. The lowest quantifiable concentration was 2.0 ng ml −1 .
The pharmacodynamic activity of donepezil was assessed This study was conducted in accordance with the principles stated in the Declaration of Helsinki. The protocol by measuring AChE activity in peripheral rbc membranes. was approved by the Institutional Review Board for Investigations Involving Human Subjects, Harris
Pharmacokinetic assessments Laboratories, Lincoln, Nebraska, USA, and all subjects gave written informed consent prior to participation.
Model-independent pharmacokinetic parameters were determined using standard techniques. The peak plasma concentration (C max ), minimum plasma concentration (C min ), and Protocol the time at which the peak concentration occurred (t max ) were determined by inspection of individual subject data. The study was double-blind, randomized and placebocontrolled. Donepezil was administered in oral doses of 1,
The area under the donepezil concentration versus time curve (AUC ) was calculated by the linear trapezoidal 3 and 5 mg once daily for 21 days, according to a sequentialgroup design. The dose range chosen for the study was rule using the data collected on days 1, 7, 14 and 21. On each of these study days, the preterminal disposition rate based upon the results of Japanese phase I studies and on the results of a single-dose study conducted in the USA constant of donepezil (l 1 ) was estimated by least-squares regression of the natural logarithm of donepezil plasma [15] . A sufficient number of subjects was enrolled to allow eight subjects to complete each dose evaluation period.
concentration versus time. The terminal disposition rate constant (l z ) was estimated following the last dose on Within each cohort of eight subjects, two were randomized to receive placebo and six to receive donepezil. The trial day 21. The terminal half-life (t D ) was calculated as 0.693/l z . Time-averaged total clearance at steady state (CL ss /F), was blinded by using a standard daily dosage of three tablets per patient. Each dose comprised donepezil (1 mg or 2 mg) adjusted for systemic bioavailability (using factor F), was expressed as the ratio of the daily dose divided by the day 21 and/or placebo tablets depending upon the treatment that was being administered. Progression to the next higher dose value of AUC . The apparent volume of distribution ( V lz /F) (also adjusted for bioavailability using factor F) was level required demonstration that the previous dose had been well tolerated.
estimated from the daily dose divided by the product of day 21 AUC (0-2 ) and l z . The average steady-state Statistical analysis concentration of donepezil (C ss ) attained in each subject Data obtained from placebo-treated subjects were pooled was estimated as the day 21 AUC divided by 24 h, on across doses for statistical comparison. The relationships the assumption that steady-state conditions had been achieved between l z , AUC, and dosage and duration of treatment by the end of the third week of drug administration.
were assessed by analysis of variance and multiple linear The accumulation (R A ) of donepezil at steady state was regression. Associations between C ss and AUC at steady calculated as AUC (0-24) on day 21 divided by AUC (0-24) on state, and daily dosage were assessed by linear least-squares day 1. These values were compared with the predicted regression. Plasma concentrations of donepezil on days 1 accumulation which was estimated from the terminal and 21 were examined by orthogonal least-squares regression. disposition rate constant and the dosing interval (i.e.
Areas under the effect-time curve (AUE (0-24) ) for rbc-1/1−e −l z t ). AChE inhibition were calculated using the linear trapezoidal rule with data obtained on days 1, 7, 14 and 21. Orthogonal Pharmacodynamic assessments linear least-squares regression analysis was used to compare these integrated measures of effect with overall systemic The pharmacodynamic activity of donepezil was based upon exposure to donepezil (AUC ). the inhibition of rbc-AChE activity measured using a
The relationship between rbc-AChE inhibition and specific and sensitive radioenzyme assay [17] . In this method, donepezil plasma concentration was examined individually [ 3 H-acetyl]choline was incubated at 4°C with homogenized in each subject, as well as in data pooled across subjects and erythrocytes containing unknown concentrations of donepedoses. Both linear and classic E max models were fit to the zil. After 30 s, the hydrolytic product was extracted into a data. Non-linear regression analyses were used to evaluate scintillation cocktail and total radioactivity was counted.
the relationships. Activity from patient samples was quantified using standard
The incidence of adverse events in donepezil-and curves of percent rbc-AChE inhibition versus the natural placebo-treated subjects within each dose group were logarithm of the donepezil concentration (ng g −1 erythrocompared using Fisher's exact test. Haematology, clinical cytes). Parameters calculated were minimal, maximal and chemistry and routine urinalysis results were also compared steady-state values of AChE inhibition ( E min , E max and E ss , with normal ranges for deviations. Shift tables were used to respectively), the concentration of donepezil required to identify trends in the data. reduce AChE activity by 50% (EC 50 ), and the area under the effect curve (AUE). Values are expressed as percent Results inhibition of pre-drug rbc-AChE activity.
Subjects Safety assessments
A total of 27 male subjects were enrolled in this study. The three dose groups were comparable with respect to age, All adverse events that were spontaneously reported by height and weight ( Table 1 ). All of the subjects assigned to a subject or elicited/observed by the investigator were treatment with placebo were Caucasian. Two subjects recorded, together with times of onset and cessation, and treated with donepezil at 1 mg day −1 and one receiving the assessments of severity and causality. Sitting blood pressures 5 mg day −1 dose were black. Two subjects were withdrawn and radial pulse rates were measured using the procedures from the study as a result of abnormal baseline laboratory described in the American Heart Association recommendavalues and did not receive any medication. A third subject tions. Assessments were made every 6 h, commencing 4 h was withdrawn after receiving ten doses of medication after the first dose and continuing until day 30.
because of his unstable alkaline phosphatase values. The A standard 12-lead ECG was recorded at screening and remaining 24 subjects completed the study without incident. at 2-day intervals beginning on day 1 and ending on day 21. ECGs were recorded at times scheduled to correspond with Pharmacokinetics the t max of donepezil (approximately 4 h after dose administration).
Model-independent pharmacokinetic parameters for donepeRoutine haematology, clinical chemistry and urinalysis zil during 21 days of once-daily oral dosing are summarized tests were performed following a 12 h fast on days 1 ( prein Table 2 . Regression analysis of individual subject data drug), 7, 14 and 21. Haematological assessments included indicated that the daily dose and duration of administration haemoglobin, haematocrit, red blood cell count, platelet count, white blood cell count and differential. Clinical examination of the urine sediment. were both significant determinants of AUC ( P<0.001 for was probably related to a reduced V lz /F at the higher doses, as this value was significantly larger in the 1 mg group both). AUC , respectively; P<0.005; ANOVA). The change state was achieved between days 14 and 21.
As shown in Table 3 , C ss and AUC were dose in l z resulted in a calculated mean half-life (±SD) of 98.2±29.8, 72.9±10.1 and 67.3±9.9 h in the 1, 3 and proportional. There were statistically significant correlations between AUC (0-24) on days 1 and 21; the regression 5 mg dose groups, respectively (Table 2) . coefficient (r 2 ) for this correlation was 0.89 ( P<0.0001) and for the correlation between AUC (0-24) on day 1 and at Pharmacodynamics steady state it was 0.82 ( P<0.0001). Similarly, there were linear relationships between AUC (0-24) at steady state and
In parallel with the increasing AUC , the extent of AChE inhibition increased throughout the treatment period C min (r 2 =0.91; P<0.0001) as well as C max (r 2 =0.83; P<0.0001) on day 1. (Figure 1 ). AUE was dependent on both dose and duration of treatment ( P<0.0001, two-way ANOVA). Pairwise As shown in Table 4 , there was good agreement between the observed accumulation of donepezil in plasma and that comparisons showed that the AUE on day 7 was significantly greater than on day 1. However, there were no significant predicted on the basis of l z . The observed accumulation factor was independent of dosage (ANOVA, P >0.5).
differences in the values of AUE on days 7, 14 and 21, suggesting that pharmacodynamic steady state was achieved The clearance of donepezil during once-daily administration was linear, as evidenced by significant regression after 7 days on donepezil treatment. In the majority of subjects there was a predictable coefficients for the correlations between dose and AUC at steady state (r 2 =0.92; P<0.0001) and between dose and relationship between rbc-AChE inhibition and plasma concentration of donepezil, and fluctuations in rbc-AChE C ss (r 2 =0.92; P<0.0001). The estimated terminal disposition rate constants for donepezil were dose dependent. However, since clearance was unchanged, this difference AUE for rbc-AChE inhibition.
Figure 2
Relationship between AUE and AUC during administration of donepezil to healthy male volunteers for 21 Figure 3 The relationship between rbc-AChE inhibition and days.
donepezil plasma concentration described by the E max model.
inhibition within the dosing interval mirrored fluctuations These were all mild in intensity and transient. The difference in donepezil concentration. AUE was strongly correlated in the incidence of adverse events between donepezil-and with AUC irrespective of the dose or duration of treatment placebo-treated subjects within each dosage group was not ( P<0.0001; Figure 2 ). The regression coefficient for this statistically significant ( P >0.05, Fisher's exact test). association (r 2 =0.919) suggests that approximately 90% of the inter-individual differences in AChE inhibition can be ascribed to inter-subject variability in donepezil disposition. Discussion In nine of 12 subjects receiving the lower donepezil doses
The disposition of donepezil, administered at 1, 3 or 5 mg of 1 or 3 mg day −1 , the effect-plasma concentration profiles oral doses once daily for 21 consecutive days, appeared to were best approximated by linear model kinetics. The mean be dose proportional. Small but statistically significant doseslope of the lines obtained for these nine subjects was dependent effects were observed in the terminal disposition 2.8±1.2% ng −1 ml, corresponding to the predicted mean rate constant and in the apparent volume of distribution. (±SD) increase in AChE inhibition per unit (ng ml −1 ) These differences may reflect concentration-dependent increase in donepezil plasma concentration. Further, their binding to tissue or blood components. However, these mean y-axis intercept (1.1±2.2%) was not statistically effects offset one another and, as such, no dose-dependent different from zero.
behaviour was observed for total clearance. The area under On the other hand, the effect-plasma concentration the concentration-time curve was linearly related to the profiles for all six subjects receiving the higher 5 mg day resulted in a slow approach to steady state. Steady state was group were best described by the E max model, as expected reached between 2 and 3 weeks after initiation of dose for enzyme activity. Estimates from the E max model in these administration. Once-daily dose administration resulted in a subjects suggested that a mean plasma concentration of four-to sixfold accumulation in plasma donepezil concen-28.7±3.9 ng ml −1 donepezil was required to produce EC 50 , tration (until steady state), with the ratio of accumulation and that the theoretical value of E max was 105.7±16.2%.
being consistent across doses. Strong linear correlations This mean value for E max was in good agreement with the (r 2 >0.8) were observed for concentration determinations theoretically predicted value of 100% inhibition at high on day 21 (AUC or C ss ) compared with day 1 ( peak donepezil concentrations. concentration, trough concentration or concentration 4 h When the individual concentration-effect data from all after drug administration). The strongest relationship was subjects were pooled, the E max model was shown to be between steady-state AUC or C ss and day 1 trough slightly superior to the linear effect model in fitting the concentration. These observations suggest that (a) the pooled data (Figure 3 ). The linear effect model then pharmacokinetics of donepezil are unchanged during a predicted an average increase in AChE inhibition per unit 3-week course of administration, and (b) the eventual (ng ml −1 ) increase in donepezil plasma concentration of steady-state concentration may be predicted with a high 2.0±0.03%, with an increased y-axis intercept of 4.6±0.4%.
degree of accuracy from a single concentration determined Similarly, the E max model for all the individual data from on the first day of drug administration. the 18 subjects yielded values of 26.2±1.2 ng ml −1 and It is generally recognized that cholinesterase inhibitors 104.4±1.1% for EC 50 and E max , respectively (Figure 3) .
that have a clinical effect in patients with Alzheimer's disease counteract the cholinergic deficit in the central nervous Safety system by inhibiting the hydrolytic action of AChE rather than BuChE [12] . Donepezil has been shown to be 1200 Donepezil was well tolerated by all subjects, with no clinically significant changes in laboratory, ECG or vital sign times more selective for AChE than for BuChE [11] . In this study, inhibition of rbc-AChE in healthy volunteers parameters observed at any dose. Adverse events that were spontaneously reported or observed by the investigator was used as a marker for assessing the pharmacodynamic action of donepezil. It was found that the extent of rbcincluded nausea, insomnia, diarrhoea, headache and dizziness.
